Proklama is developed by Geophyt S.r.l.s..

What development phase is Proklama in?

Proklama is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Proklama

Geophyt S.r.l.s. · FDA-approved active Small molecule Quality 0/100

Proklama, marketed by Geophyt S.r.l.s., is a drug with a key composition patent expiring in 2028. The primary strength of Proklama lies in its current market presence, leveraging its established position before patent expiry. The primary risk is the potential increase in competition post-2028, as generic versions may enter the market.

At a glance

Generic name	Proklama
Sponsor	Geophyt S.r.l.s.
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Pain Relief In Irritable Bowel Syndrome (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Proklama CI brief — competitive landscape report
Proklama updates RSS · CI watch RSS
Geophyt S.r.l.s. portfolio CI